MediciNova gains approval to present abstract on ALS therapy MN-166
Category: #Health  By Paroma Bhattacharya  Date: 2019-07-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

MediciNova gains approval to present abstract on ALS therapy MN-166

The company CMO, Kazuko Matsuda will present the abstract titled “Interaction (nonuniformity) of ALS Progression and the Efficacy of MN-166 (ibudilast)” at the 30th International Symposium.

MediciNova, Inc., a biopharmaceutical organization focused on developing small-molecule therapeutics for the treatment of diseases that lack clinical cure, recently announced that an abstract concerning its completed clinical trial of MN-166 (ibudilast) in ALS has been approved for presentation at the 30th International Symposium on Amyotrophic Lateral Sclerosis/Motor Neurone Disease (ALS/MND), scheduled in Perth, Australia. 

Speaking on the move, Dr. Yuichi Iwaki, President and Chief Executive Officer, MediciNova, said that the company is delighted to present its research on ALS at the 30th International Symposium on ALS/MND. He said that their firm will use this opportunity to share its study and results with all the ALS/MND researchers, patients and clinicians who initially laid the foundation of design and implementation of its upcoming ALS trial.  

Reportedly, the pilot was a double-blind, randomized, placebo-controlled study which involved six-month treatment period accompanied by a six-month open-label extension. In collaboration with Carolinas Neuromuscular/ALS-MDA Center’s Director, Dr. Benjamin Rix Brooks, MediciNova offered patients a dose of 60 mg of MN-166 per day in both early and last stage of ALS.

For the record, amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that damages nerve cells in the spinal cord and the brain. The nerves lose the ability to prompt specific muscles, which makes the muscles weak. The condition affects voluntary movement of patients which results to complete paralysis in the later stages. Generally, an ALS patient’s life expectancy lasts between 2-5 years.

However, MN-166 (ibudilast)'s neuroprotective and anti-neuroinflammatory actions provide the rationale for treatment of ALS, progressive MS (multiple sclerosis) and other neurological diseases like glioblastoma (GBM), and substance addiction/abuse. These actions have also been demonstrated in preclinical and clinical studies, cite reports.

Source Credit: https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-4



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...